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Abstract: Leptin has been suggested to play a role in amyotrophic lateral sclerosis (ALS), a fatal
progressive neurodegenerative disease. This adipokine has previously been shown to be associated
with a lower risk of ALS and to confer a survival advantage in ALS patients. However, the role
of leptin in the progression of ALS is unknown. Indeed, our understanding of the mechanisms
underlying leptin’s effects in the pathogenesis of ALS is very limited, and it is fundamental to
determine whether alterations in leptin’s actions take place in this neurodegenerative disease. To
characterize the association between leptin signaling and the clinical course of ALS, we assessed
the mRNA and protein expression profiles of leptin, the long-form of the leptin receptor (Ob-Rb),
and leptin-related signaling pathways at two different stages of the disease (onset and end-stage) in
TDP-43A315T mice compared to age-matched WT littermates. In addition, at selected time-points, an
immunoassay analysis was conducted to characterize plasma levels of total ghrelin, the adipokines
resistin and leptin, and metabolic proteins (plasminogen activator inhibitor type 1 (PAI-1), gastric
inhibitory peptide (GIP), glucagon-like peptide 1 (GLP-1), insulin and glucagon) in TDP-43A315T
mice compared to WT controls. Our results indicate alterations in leptin signaling in the spinal cord
and the hypothalamus on the backdrop of TDP-43-induced deficits in mice, providing new evidence
about the pathways that could link leptin signaling to ALS.
Keywords: neurodegenerative disease; amyotrophic lateral sclerosis (ALS); metabolism; leptin; long
leptin receptor (Ob-Rb); TAR DNA binding protein (TDP-43)
1. Introduction
Amyotrophic lateral sclerosis (ALS) is an irreversible neurodegenerative disorder
characterized by the selective and progressive loss of upper and lower motor neurons
of the cerebral cortex, brainstem, and spinal cord [1]. ALS is fast becoming a major
health and socio-economic challenge for many countries around the world; however, no
current therapeutic disease-modifying intervention exists. Although the cellular basis for
neurodegeneration in ALS is not yet fully understood, numerous studies have shown that
the underlying disease process involves multiple complex genetic and non-genetic factors,
including metabolic alterations.
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Included amongst the underlying metabolic alterations in ALS is leptin, a polypeptide
hormone secreted primarily by adipocytes that exerts an important role in regulating food
intake and energy balance through actions in the brain [2,3]. Leptin acts by binding to its
receptors that are structurally related to the cytokine receptor class I family. Alternative
splicing generates distinct isoforms of the leptin receptor, including long (Ob-Rb) and short
isoforms (Ob-Ra and Ob-Rc-f), with Ob-Rb being thought to transmit the majority of lep-
tin’s biological signals [4]. However, in addition to its classical role in the neuroendocrine
regulation of food intake, the existence of its receptors in extra-hypothalamic brain regions
strongly suggests that leptin affects other biological processes. Indeed, studies indicate
that leptin is strongly involved in the central nervous system (CNS) [5,6] and neurological
disorders [7–9] through mechanisms of action involving its four major signal transduc-
tion pathways, Janus tyrosine kinase/signal transducer and activator of transcription
(JAK/STAT), extracellular signal-regulated kinase pathway (ERK), phosphatidylinositol
3-kinase (PI3K)/Akt, and mitogen-activated protein kinase (MAPK)/sirtuin 1 (SIRT1),
downstream of Ob-Rb receptors (King et al. 2018; Zhang and Chua, 2018). Leptin is
reported to be involved in ALS [10]; however, our understanding of the underlying bi-
ological mechanisms of leptin’s actions in the pathogenesis of ALS is limited, although
both clinical and epidemiological studies support the concept that altered leptin levels
contribute to the pathogenesis of ALS [11]. A recent epidemiological study determined
that leptin levels are inversely associated with ALS outcome [12]; increasing leptin con-
centrations were associated with longer survival of ALS patients, which highlights the
possible link between leptin and the clinical outcome of ALS. Altered peripheral levels
of leptin have been recently reported in patients with ALS and frontotemporal dementia
(FTD) [13], which exists on a continuous clinical spectrum with ALS [14]. Interestingly,
new epidemiological data suggest that increased dietary fat intake (high-fat diet; HFD),
which significantly increases leptin levels, may reduce the risk of developing ALS [15–17].
A positive correlation between plasma leptin and body mass index (BMI) was observed
in ALS patients [11]. Nevertheless, a study in SOD1G93A mice has suggested that leptin
reduction or loss is beneficial and slows disease progression [10], while other studies have
investigated the potential therapeutic impact of HFD consumption, which induces obesity
and increases leptin levels, in mutant SOD1 mice [18–21] and report beneficial effects in
terms of survival and improved motor behavior. Therefore, the information to date is insuf-
ficient to clarify the role of leptin in ALS or the possible pathways that link this adipokine
to the pathogenesis of this disease. A greater understanding of leptin signaling in ALS is
needed to determine whether leptin pathways are causally connected to ALS pathogenesis.
In this context, we examined leptin-related pathways during different ALS stages
(onset and end-stage of disease) in TDP-43A315T mice [22], which recapitulate several
aspects of the human disease. We examined the status of leptin signaling under the
backdrop of pathological CNS TDP-43 levels providing, to our knowledge, the first insights
into the association between the pathways that link alterations in leptin signaling to the
pathogenesis of ALS.
2. Methods
2.1. Colony Maintenance and Mice Monitoring
Transgenic (Tg) TDP43A315T mice (strain no. 010700, Jackson Laboratory, Bar Harbor,
ME, USA) and the genetic background-matched wild type (WT) littermate control mice
were used in this study [22]. This mouse model of ALS expresses a mutant human TAR
DNA binding protein TDP-43 cDNA harboring an N-terminal Flag tag and an A315T amino
acid substitution associated with ALS mainly in the CNS [22,23]. To avoid the ambiguity
associated with reported sex-related differences in mean survival time of TDP-43A315T
mice [22,23], only male mice were used. Animals expressing the hTDP-43 transgene were
confirmed via PCR according to the distributor’s protocol. The ALS-like disease was
divided into two stages: onset (defined as the last day of individual peak body weight
before a gradual loss occurs) and the end-stage of disease (defined as when weight is 20%
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below the initial weight on three consecutive days), at which the mice were euthanized. The
end-stage is typically reached 2–4 weeks after symptom onset. Animals were group-housed
under standard housing conditions with a 12 h light–dark cycle, and food and water ad
libitum. To monitor disease onset and progression, all mice were weighed and assessed
three times per week until the disease onset-stage, after which they were checked daily in
the morning until the disease end-stage. All experimental procedures were approved by
the Animal Ethics Committee of the National Hospital for Paraplegics (HNP) (Approval No
26/OH 2018) in accordance with the Spanish Guidelines for the Care and Use of Animals
for Scientific Purposes.
2.2. Tissue Preparation
Animals were terminally anesthetized with sodium pentobarbitone (140 mg/kg) and
transcardially perfused with room temperature 0.01 M phosphate-buffered saline (PBS;
pH 7.4), in the middle of the light cycle (between 11 AM and 1 PM). Blood was collected
and processed as previously described [24]. Gonadal white adipose tissue (WAT), the
hypothalamus, and lumbar spinal cord from each animal were processed to extract both
mRNA and proteins for real-time PCR and Western blotting analysis. Samples were
immediately frozen on dry ice and stored at −80 ◦C for later analysis.
2.3. RNA Isolation and RT-qPCR
Total RNA was extracted following the instructions of the RNeasyPlus Mini Kit
(Qiagen, Hilden, Germany). Absorbance at 260 nm was measured using a NanoDrop
(ThermoFisher, Waltham, MA, USA) to determine RNA concentrations. For WAT and
spinal cord samples, complementary DNA (cDNA) was synthesized from 1 µg of total RNA
as previously described [25]. Relative quantification of leptin (assay ID: Mm00434759_m1)
and Ob-Rb (assay ID: Mm00440181_m1) was performed using 10 ng of reverse-transcribed
total RNA in TaqMan One-Step real-time PCR Master Mix (PE Applied Biosystem, Foster
City, CA, USA). Each sample was run in duplicate and β-Actin (assay ID: Mm00607939_s1)
was used as a control to normalize gene expression. The reactions were run on an ABI
PRISM 7900 Fast Sequence Detection System instrument and software (Applied Biosystem,
Foster City, CA, USA) according to the manufacturer’s protocol.
Furthermore, for the hypothalamus samples, cDNA was synthesized from 1 µg of
total RNA by using the NZY First-Strand cDNA Synthesis Kit (NZYTech, Lisbon, Portu-
gal). Quantitative real-time PCR was performed by using assay-on-demand kits (Applied
Biosystems). NZY qPCR Probe Master Mix (NZYTech, Lisbon, Portugal) was used for
the PCR reaction according to the manufacturer’s protocol in a QuantStudio3 Detection
System (Applied Biosystems, Foster City, CA, USA). Each sample was run in duplicate
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; assay ID: 4352339E) was used
as a control to normalize gene expression. The primers and probes used were Ob-Rb
(assay ID: Mm00440181_m1), pro-opiomelanocortin (POMC; assay ID: Mm00435874_m1),
Agouti-related protein (Agrp; assay ID: Mm00475829_g1), and neuropeptide Y (NPY; assay
ID: Mm03048253_m1). In all cases, relative quantification for each gene was performed by
the ∆∆Ct method [26].
2.4. Protein Extraction and Western Blot Analysis
Proteins were extracted from spinal cord tissue using RIPA buffer (Sigma-Aldrich,
Saint Louis, MO, USA) containing a cocktail of protease inhibitors (Roche, Basel, Switzer-
land). For the hypothalamic samples, the supernatant collected in the RNA extraction
was diluted in acetone and frozen. Afterwards, samples were centrifuged, and proteins
from the hypothalamus were re-suspended in 100 µL of CHAPS buffer (7M urea, 2M
thiourea, 4% CHAPS, and 0.5% Tris-HCl 1M, pH 8.8). In all cases, protein concentration
was measured using the BioRad protein assay based on the Bradford method. Samples were
measured at 595 nm on an automatic microplate analyzer (Tecan Infinite M200, Grödig,
Austria). Denatured proteins (30 µg for spinal cord and 20 µg for hypothalamus samples,
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respectively) were resolved using 8%, 10%, or 12% SDS-PAGE (depending on the molecular
weight of the protein assayed) and transferred onto PVDF membranes. Membranes were
blocked with TBS with 0.1% Tween 20, and 5% BSA or non-fat dried milk and incubated
overnight at 4 ◦C with the primary antibody in blocking buffer. The primary antibodies
used for the spinal cord samples were: rabbit anti-Ob-Rb (1:500; Abcam, Cambridge, UK),
rabbit anti-Akt (1:1000; Cell Signaling, Danvers, MA, USA), rabbit anti-Akt (Ser473) (1:1000;
Cell Signaling, Danvers, MA, USA), rabbit anti-STAT3 (1:500; Santa Cruz), and rabbit anti-
STAT3 (Tyr705) (1:1000; Cell Signaling, Danvers, MA, USA). The primary antibodies used
for the hypothalamic samples were: rabbit anti-LepR: (1:250, Santa Cruz, Dallas, TX, USA);
mouse phospho-Akt Ser473 (1:500; Cell Signaling, Danvers, MA, USA), rabbit anti-Akt
(1:1000 Santa Cruz, Dallas, TX, USA); mouse anti-STAT3 (1:1000; Cell Signaling, Danvers,
MA, USA), and rabbit anti-phospho STAT3 (Tyr705) (1:500; Cell Signaling, Danvers, MA,
USA); and rabbit anti-suppressor of cytokine signaling 3 (SOCS3) (1:1000; Proteintech,
Rosemont, IL). A corresponding anti-rabbit or anti-mouse horseradish peroxidase (HRP)-
conjugated secondary antibody at a dilution of 1:7000 (Dako) or 1:2000 (Pierce, Rockford,
IL, USA) for spinal cord and hypothalamus samples, respectively, were used. Mouse
anti-GAPDH (1:5000, Millipore, Burlington, MA, USA) and/or mouse anti-actin (1:1000;
ThermoFisher, Waltham, MA, USA) were used as the loading controls. Peroxidase activity
was visualized by using Immune-Clarity Western Chemioluminiscent substrate (BioRad,
Hercules, CA, USA) and determined by densitometry using an ImageQuant LAS 4000 mini
system (GE Healthcare, Little Chalfont, United Kingdom). Band intensity was measured as
the integrated intensity using ImageJ software (v1.4; NIH). All data were normalized to
control values on each membrane.
2.5. Measurement of Metabolic Markers in Plasma
Total ghrelin, the adipokines resistin and leptin, and metabolic biomarkers of insulin
resistance (GIP, GLP-1, glucagon, PAI-1, and insulin) from plasma samples were analyzed
in duplicate by using the Bio-PlexPro mouse Diabetes group from Bio-Rad (Ref. 171F7001M,
Hercules, CA, USA) and Luminex® 200TM technology as previously described [27]. Sam-
ples were processed following the manufacturer’s instructions. According to Bio-Rad’s
information, the intra- and inter-assay CV variability is <20%. The final concentration
value of each metabolic marker was the result of the mean from the duplicate measures.
2.6. Statistical Analysis
All data are presented as the mean ± standard error of the mean (SEM). Differences
between means were assessed by two-way ANOVA followed by Dunnett’s post hoc test,
to compare all groups with control WT onset mice, and Tukey’s post hoc test was used
for multiple comparisons between all groups. For multiplex assays, the mean of each
experimental group was determined for all the analytes, and the Kruskal–Wallis test was
performed followed by Dunnett’s post hoc test to compare all groups with onset stage,
while Bonferroni post hoc test was used for multiple comparisons between all groups. For
all statistical tests, a p-value of <0.05 (CI 95%) was assumed to be significant. Statistical
analysis was performed using GraphPad Prism software (version 8.3.1).
3. Results
3.1. Leptin Levels Are Altered in WAT of TDP-43A315T Mice
Experimental data are limited regarding the status of leptin during the progression of
ALS, even though this hormone is historically known for its important role in regulating
body weight, and mild obesity appears to improve survival in ALS patients [28]. Thus, to
determine the leptin expression profile in WAT, the primary source of leptin production, we
first examined the levels of leptin mRNA in different phases of the disease in TDP-43A315T
mice compared to age-matched WT littermates (Figure 1). RT-qPCR analysis demonstrated
marked differences in the expression profile of the leptin transcript during the clinical course
of the disease in TDP-43A315T mice compared with WT samples. There was a significant
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effect of genotype (p = 0.001) and disease progression (p = 0.002) in the expression profile
of leptin mRNA in WAT (Figure 1). Indeed, although we [24] and others [23,29–31] have
previously reported that TDP-43A315T mice exhibit weight loss during disease progression,
Tukey’s post hoc test demonstrated a statistically significant up-regulation of leptin mRNA
levels in WAT at the onset stage in TDP-43A315T mice, followed by a significant increase in
its mRNA expression at the end-stage of disease compared to age-matched WT littermates
(p = 0.02 and p = 0.03, respectively; Figure 1).
Int. J. Mol. Sci. 2021, 22, 10305 5 of 14 
 
 
to determine the leptin expression profile in WAT, the primary source of leptin produc-
tion, we first examined the levels of leptin mRNA in different phases of the disease in TDP-
43A315T mice compared to age-matched WT littermates (Figure 1). RT-qPCR analysis 
demonstrated marked differences in the expression profile of the leptin transcript during 
the clinical course of the disease in TDP-43A315T mice compared with WT samples. There 
was a significant effect of genotype (p = 0.001) and disease progression (p = 0.002) in the 
expression profile of leptin mRNA in WAT (Figure 1). Indeed, although we [24] and others 
[23,29–31] have previously reported that TDP-43A315T mice exhibit weight loss during dis-
ease progression, Tukey's post hoc test demonstrated a statistically significant up-regula-
tion of leptin mRNA levels in WAT at the onset stage in TDP-43A315T mice, followed by a 
significant increase in its mRNA expression at the end-stage of disease compared to age-
matched WT littermates (p = 0.02 and p = 0.03, respectively; Figure 1).  
 
Figure 1. Alterations in leptin expression in the WAT in TDP-43A315T mice. Leptin mRNA expression 
was assessed by RT-qPCR in TDP-43A315T mice compared to age-matched WT littermates at both 
onset and end-stage of disease. Values are expressed as the mean ± SEM for the different groups (n 
= 5 per genotype/stage of disease). Comparison between groups was performed by two-way 
ANOVA followed by Dunnett’s post hoc test to compare all groups with WT onset stage, while 
Tukey’s post hoc test was used for multiple comparisons between all groups, where * p < 0.05 vs. 
WT onset stage; ** p < 0.05 vs. WT end-staged. Abbreviations: WAT, white adipose tissue. 
3.2. Peripheral Levels of Leptin, Ghrelin, and Resistin Are Altered in Plasma of TDP-43A315T 
Mice 
Circulating leptin levels were reduced in both ALS stages in TDP-43A315T mice com-
pared to age-matched controls, being significantly lower at disease termination in the af-
fected mice (F(3, 12)=3.875, p = 0.03; Figure 2A). Ghrelin and resistin levels also showed dif-
ferences between the ALS stages, as well as genotype-specific differences (Figure 2B–C). 
Dunnett’s post hoc test demonstrated a significant increase in total ghrelin concentrations 
in both WT and TDP-43A315T mice at the end-stage of disease compared to the onset stage 
(p = 0.01 and p = 0.007, respectively; Figure 2B). Circulating resistin concentrations were 
lower in TDP-43A315T mice compared to age-matched WT littermates, with this reaching 
statistical significance at the end-stage of disease (p = 0.001; Figure 2C). 
To further analyze metabolism, circulating levels of PAI-1, GIP, GLP-1, insulin, and 
glucagon peptides were measured in TDP-43A315T and age-matched WT littermates at both 
time-points of the disease. No statistically significant differences were found between 
TDP-43A315T and WT mice at either of the time-points analyzed (Figure 2F–H); however, 
Dunnett’s post hoc test demonstrated a significant increase in PAI-1 peptide concentra-
tions in TDP-43A315T mice at the end-stage of the disease compared to circulating PAI-1 
levels in WT mice at the onset stage (p = 0.02; Figure 2D). Indeed, no linear correlation was 
found using Spearman’s test among the plasma levels of these metabolic proteins in WT 
controls or TDP-43A315T mice throughout the clinical course of the disease (data not 
shown).  
Figure 1. Alterations in leptin expression in the WAT in TDP-43A315T mice. Leptin mRNA expression
was assessed by RT-qPCR in TDP-43A315T mice compared to age-matched WT littermates at both
onset and end-stage of disease. Values are expressed as the mean ± SEM for the different groups
(n = 5 per genotype/stage of di ase). Comparison between groups was performed by two-way
ANOVA followed by Dunnett’s post hoc test to compare all groups with WT onset stage, while
Tukey’s post hoc test was used for multiple comparisons between all groups, where * p < 0.05 vs. WT
onset stage; ** p < 0.05 vs. WT end-staged. Abbreviations: WAT, white adipose tissue.
3.2. Peripheral Levels of Leptin, Ghrelin, a i las a of TDP-43A31 Mice
Circulating leptin levels were reduced in both ALS stages in TDP-43A315T mice com-
pared to ge-matched controls, being significantly lower at disease termination in the
ffected mice (F(3, 12)=3.875, p = 0.03; Figure 2A). Ghr lin and re is in levels also s owed
differen s between the ALS stages, as well as genotype-specific diff rences (Figure 2B,C).
Dunnett’s post hoc test demon tr ted a significant increase n total ghrelin concentrations
in both WT and TDP-43A315T mice at the end-stage of di ase compa d to the o set stage
(p = 0.01 and p = 0.007, respectively; Figure 2B). Circulating resistin concentration were
lower in TDP-43A315T mice ompared to age-matched WT littermates, with this reaching
statistical significance at the end-stage of dise se (p = 0.001; Figure 2C).
To further a alyze metabolism, circulating levels of PAI-1, GIP, GLP-1, insulin, and
glucagon peptides were measured in TDP-43A315T and age-matched WT littermates at both
time-points of the disease. No statistically significant differences were found between
TDP-43A315T and WT mice at either of the time-points analyzed (Figure 2F–H); ho ever,
Dunnett’s post hoc test demonstrated a significant increase in PAI-1 peptide concentrations
in TDP-43A315T mice at the end-stage of the disease compared to circulating PAI-1 levels in
WT mice at the onset stage (p = 0.02; Figure 2D). Indeed, no linear correlation was found
using Spearman’s test among the plasma levels of these metabolic proteins in WT controls
or TDP-43A315T mice throughout the clinical course of the disease (data not shown).




Figure 2. Adipocytokines and metabolic biomarkers levels in WT controls and TDP-43A315T mice. 
Total plasma leptin (A), ghrelin (B) and the adipokine resistin (C), and (D–H) metabolic biomarkers 
of insulin resistance (PAI-1, GIP, GLP-1, insulin, and glucagon) were measured over the time course 
of the disease in TDP-43A315T mice compared to age-matched WT littermates using Luminex® 200TM 
technology. Values are expressed as the mean ± SEM for the different groups (n = 5 per geno-
type/stage of disease). Kruskal–Wallis test was performed followed by Dunnett’s post hoc test to 
compare all groups with WT onset stage, while Bonferroni post hoc test was used for multiple com-
parisons between all groups, where * p < 0.05 vs. WT onset stage; # p < 0.05 vs. TDP-43A315T onset; ** p 
< 0.05 vs. WT end-staged. Abbreviations: PAI-1, plasminogen activator inhibitor type 1; GIP, gastric 
inhibitory peptide; GLP-1, glucagon like peptide 1. 
3.3. Hypothalamic Leptin Signaling in TDP-43A315T Mice 
We next studied how leptin signaling and leptin-sensitive genes involved in metab-
olism were affected in the hypothalamus of TDP-43A315T mice over the time course of the 
disease. RT-qPCR analysis demonstrated a significant effect of genotype (p = 0.001) and 
disease progression (p = 0.002) on the expression profile of Ob-Rb mRNA in the hypothal-
amus (Figure 3A). Dunnett’s post hoc test showed that Ob-Rb mRNA levels were upregu-
lated in the hypothalamus of TDP-43A315T mice at both time points of the disease compared 
Figure 2. Adipocytokines and metabolic biomarkers levels in T controls and TDP-43A315T mice.
tal las a le ti ( ), reli ( ) a t e a i i e resisti ( ), a ( – ) eta lic i ar ers
i l , , ,
the disease in TDP-43A315T mice compared to age-matched WT littermates using Luminex®
200TM technology. Values are expressed as the mean ± SEM for the different groups (n = 5 per
genotype/stage of disease). Kruskal–Wallis test was performed followed by Dunnett’s post hoc test
to compare all groups with WT onset stage, while Bonferroni post hoc test was used for multiple
comparisons between all groups, where * p < 0.05 vs. WT onset stage; # p < 0.05 vs. TDP-43A315T
onset; ** p < 0.05 vs. WT end-staged. Abbreviations: PAI-1, plasminogen activator inhibitor type 1;
GIP, gastric inhibitory peptide; GLP-1, glucagon like peptide 1.
3.3. Hypothalamic Leptin Signaling in TDP-43A315T Mice
We next studied how leptin signaling and leptin-sensitive genes involved in metabolism
were affected in the hypothalamus of TDP-43A315T mice over the time course of the disease.
RT-qPCR analysis demonstrated a significant effect of genotype (p = 0.001) and disease
progression (p = 0.002) on the expression profile of Ob-Rb mRNA in the hypothalamus
(Figure 3A). Dunnett’s post hoc test showed that Ob-Rb mRNA levels were upregulated
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in the hypothalamus of TDP-43A315T mice at both time points of the disease compared to
age-matched WT controls (p = 0.03 and p = 0.001, respectively; Figure 3A). In addition, as
central hypothalamic leptin signaling has a critical role in promoting energy homeostasis
via modulation of food intake and energy expenditure [32], we also investigated the mRNA
levels of POMC, AgRP, and NPY neuropeptides (Figure 3B–D), that play essential roles
in the regulation of food intake and energy homeostasis in mammals. RT-qPCR analysis
demonstrated differences in the pattern of expression of POMC, NPY, and AgRP genes
between TDP-43A315T and WT mice at both disease stages. There were significant effects
of genotype (p = 0.03) and disease progression (p = 0.0007) in the expression profile of
POMC mRNA in the hypothalamus (Figure 3B), with an overall increase in POMC mRNA
with age in both genotypes. In TDP-43A315T mice POMC mRNA levels were lower than
in WT at both onset and end-stage, with this increase being significant at the end-stage of
disease compared to POMC mRNA levels in WT controls at the onset (p = 0.04; Figure 3B).
In addition, RT-qPCR analysis demonstrated a significant effect of genotype (p = 0.0009
and p = 0.0005, respectively) and disease progression (p = 0.0004 and p = 0.002, respectively;
Figure 3C,D) on the expression profile of NPY and AgRP mRNA levels in the hypothalamus.
Although Dunnett’s post hoc test demonstrated no age-dependent changes in NPY and
AgRP mRNA levels in TDP-43A315T mice compared to WT mice at the onset stage, Tukey’s
post hoc test demonstrated a statistically significant hypothalamic upregulation of both
orexigenic neuropeptides (NPY: p = 0.002, Figure 3C; and AgRP: p = 0.0007, Figure 3D) at
the end-stage of disease in the hypothalamus of TDP-43A315T mice relative to age-matched
WT controls.
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Figure 3. Alterations in Ob-Rb and anorexigenic and orexigenic neuropeptides in the hypothalamus
of TDP-43A315T mice. (A) Ob-Rb mRNA expression, (B) POMC, (C) NPY, and (D) AgRP transcripts
ere assessed by RT-qPCR in TDP-43A315T ice co pared to age- atched T litter ates at both
t -sta e of disease. Values are expre sed as the mean ± SEM for the different groups
(n = 5 per genotype/stage of disease). Comparison between groups was erfor ed
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Tukey’s post hoc test was used for multiple comparisons between all groups, where * p < 0.05 vs.
WT onset stage; # p < 0.05 vs. TDP-43A315T onset; ** p < 0.05 vs. WT end-staged. Abbreviations:
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We next investigated the protein levels of Ob-Rb (Figure 4A) and SOCS3 (Figure 4B),
the main inhibitor of leptin signaling in the brain, as well as the status of the STAT3 (pTyr705-
STAT3) and Akt (pSer473-Akt) pathways, which are downstream of the Ob-Rb receptor
(Figure 4C,D). Immunoblotting analysis demonstrated that Ob-Rb was also altered at the
protein level in TDP-43A315T mice (Figure 4A). There was a significant effect of disease
progression (p = 0.005) on the expression profile of the Ob-Rb receptor in the hypothalamus.
In contrast to mRNA levels, protein levels of the Ob-Rb receptor were lower in TDP-43A315T
mice compared to age-matched WT controls, which reached significance (p = 0.01) at
the end-stage of disease (Figure 4A). In addition, we found no significant effect of either
disease stage or genotype on SOCS3 levels (Figure 4B). There was a significant effect of
genotype (p = 0.0001) on the phosphorylation levels of Akt protein in the hypothalamus
(Figure 4C). At the end-stage of the disease, Akt phosphorylation levels were significantly
decreased in the hypothalamus of both genotypes (p = 0.001 and p < 0.0001, respectively)
compared to WT controls as well as compared to TDP-43A315T mice (p = 0.01 and p = 0.0008,
respectively) at the onset stage (Figure 4C). In addition, there was no effect of genotype or
disease progression on the phosphorylation levels of STAT3 protein in the hypothalamus
(Figure 4D).
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3.4. Leptin Signaling in the Spinal Cord of TDP-43A315T
Since leptin signaling has actions throughout the CNS [33], and the results of our study
could possibly indicate that the reduction in circulating leptin levels is associated with
altered hypothalamic leptin signaling in TDP-43A315T mice, particularly at the end-stage of
the disease, we analyzed if leptin signaling in the spinal cord tissue of TDP-43A315T mice
differed from that of WT mice. Although there was no effect of genotype, RT-qPCR analysis
demonstrated that there was a significant effect of disease progression (p = 0.01) on the
expression profile of Ob-Rb receptor in the spinal cord (Figure 5A). In addition, Tukey’s
post hoc test demonstrated a statistically significant down-regulation of Ob-Rb mRNA at
the end-stage of the disease in the spinal cord of TDP-43A315T mice relative to age-matched
WT littermates (p = 0.02, Figure 5A). In contrast, Ob-Rb protein levels were increased in
the spinal cord of TDP-43A315T mice compared to WT at both onset and end-stage of the
disease (p = 0.001 and p = 0.04, respectively; Figure 5B). In addition, there was a significant
effect of genotype (p = 0.005) and disease progression (p = 0.0006) on the phosphorylation
levels of Akt protein in the spinal cord (Figure 5C). Dunnett’s post hoc test showed that
phosphorylation levels of Akt protein was significantly upregulated in the spinal cord of
WT mice and TDP-43A315T mice at both time-points of the disease compared to WT controls
(p < 0.0001, p = 0.002 and p < 0.0001, respectively) at the onset stage (Figure 5C). Finally,
there was a significant effect of genotype (p = 0.0001; Figure 5D) on the phosphorylation
levels of STAT3 protein in the spinal cord, with levels increasing in both genotypes with age.
Indeed, Dunnett’s post hoc test demonstrated that phosphorylation levels of STAT3 protein
were significantly decreased at the end-stage of the disease in TDP-43A315T compared to
WT controls at the onset stage (p = 0.004; Figure 5D).
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(A) mRNA expression of Ob-Rb receptor was assessed by RT-qPCR in TDP-43A315T mice compared
to age-matched W littermates t both nset and end-stag of disease. Representative GAPDH-
normalized immunoblot images and quantitation of (B) Ob-Rb receptor, (C) pAkt (pSer473-Akt)
protein, (D) pSTAT3 (pTyr705-STAT3) protein in spinal extracts of TDP-43A315T mice compared to
age-matched WT littermates at the onset and end-stage of disease. Values are expressed as the mean
± SEM for the different groups (n = 5 per genotype/stage of disease). Comparison between groups
was performed by two-way ANOVA followed by Dunnett’s post hoc test to compare all groups with
WT onset stage, while Tukey’s post hoc test was used for multiple comparisons between all groups,
where * p < 0.05 vs. WT onset stage; # p < 0.05 vs. TDP-43A315T onset; ** p < 0.05 vs. WT end-staged.
In the immunoblot images, representative bands were run on the same gel but were non-contiguous.
Abbreviations: SC, spinal cord; Ob-Rb, long form of leptin receptor; SOCS3, Suppressor of cytokine
signaling 3; Akt, serine/threonine kinase; STAT3, signal transducer and activator of transcription 3.
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4. Discussion
A growing body of evidence indicates disturbances in energy metabolism in ALS [34–37],
suggesting that targeting metabolism could represent a rational strategy to treat this disease.
Metabolic abnormalities have been reported in both ALS patients [19] and mouse models
of ALS [10], as well as in the more recently developed murine model of ALS/FTD, TDP-43
proteinopathy [38,39]. Two epidemiological studies provided the first evidence of leptin as
a potential novel therapeutic target in ALS [12,40], although very little is known about the
direct influence of leptin in altering energy metabolism and disease progression in ALS,
as it has thus far been correlated with the protection exerted by increased fat mass stores.
Indeed, even though leptin signaling appears to be involved in ALS, our understanding
of its biological role in mechanisms of disease pathogenesis is limited. Here, we present
evidence of alterations in leptin signaling in the peripheral and CNS of the TDP43A315T
transgenic ALS mouse model, providing novel insights about the pathways that could link
alterations in leptin to ALS disease.
The majority of circulating leptin is produced in adipose tissue [41], with leptin mRNA
levels normally being directly correlated with adipocyte size, and high circulating levels
of this hormone are associated with obesity [41,42]. The opposite is observed in ALS
patients [43,44] as ALS causes loss of body weight, reduced fat mass, and reduced circu-
lating leptin levels. Here, we report an up-regulation of leptin mRNA levels in WAT of
TDP-43A315T mice, both at onset and at the end-stage of the disease. This observation is
of interest because peripheral leptin levels are positively correlated with adipose tissue
mass in TDP-43A315T mice, as we previously reported a progressive decline in body weight
in TDP-43A315T mice compared to WT controls [24], which is in agreement with reduced
circulating levels of this adipokine. Indeed, circulating plasma levels of leptin were lower
in TDP-43A315T mice compared to WT mice at both ALS stages, which is in accordance with
the decrease in body weight [23,29–31]. Nevertheless, although the reduction in circulating
levels of leptin is in accordance with a lower adipose tissue mass, the mRNA levels of
leptin/µg adipose tissue are upregulated in TDP-43A315T mice suggesting an attempt to
maintain normal circulating levels of this adipokine. This observation is of interest because
the evidence supports that cachexia may occur in the early course of ALS [45], even before
the loss of motor neurons and neurodegeneration begin [46]. Indeed, WAT is specialized in
the storage of triglycerides (TGs) [47] and patients with ALS suffer from hypolipidemia [36].
In this context, as adipose tissue wasting has been shown to occur before the appearance of
classical cachexia markers, as for example loss of fat mass, and subsequently, loss of body
weight, it will be interesting in future in vitro studies to determine the mechanism of leptin
regulation in primary adipocytes of mutant TDP-43. Considering that cachexia may occur
in the early stages of ALS, our results might suggest that leptin is a potential biomarker of
adipose tissue wasting, and subsequently, the muscle atrophy and depletion of fat stores
clinical features in ALS.
In addition to the marked decrease in circulating leptin concentrations, our results
confirm disease stage-dependent alterations in the circulating levels of ghrelin and resistin
in TDP-43A315T mice. Plasma levels of ghrelin, an appetite-stimulating hormone, were
highest in WT animals at the end-stage of the disease and although there was an increase
between onset and end-stage in TDP-43A315T mice they remained significantly lower
compared to WT, which could partly be due to modifications in food intake and ultimately
the loss of body weight in TDP-43A315T mice [23,29–31]. Indeed, low plasma ghrelin
levels have been found in ALS patients [11]. We also found lower circulating levels of the
adipokine resistin in TDP-43A315T mice both at the onset and end-stage of ALS disease.
This result supports previous data from our group showing downregulation of peripheral
protein resistin levels in TDP-43A315T mice [24]. However, although no difference in plasma
levels of resistin was found between controls and ALS patients [11], this data might indicate
that resistin levels are directly associated with metabolic abnormalities in TDP-43A315T
mice. However, future experiments should try to corroborate this hypothesis.
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We examined leptin signaling in the hypothalamus and spinal cord of TDP-43A315T
mice, as they represent two areas of the nervous system vulnerable to ALS, where leptin
could play an important role. In both tissues, there was an up-regulation in the expression
levels of Ob-Rb transcript in TDP-43A315T mice compared to age-matched WT littermates.
The observation in spinal cord is of particular interest as a previous study conducted in rats
showed a significant upregulation of Ob-Rb mRNA after spinal cord injury [5] and thus, our
result may reflect the progressive irreversible neurodegenerative damage that characterizes
ALS pathogenesis. Alternative splicing of the ObR gene generates distinct isoforms of the
leptin receptor, including long (Ob-Rb) and short isoforms (Ob-Ra and Ob-Rc-f) that differ
in the length of their intracellular cytoplasmic domains, a region that contains specific
motifs involved in leptin signaling [48,49]. In this context, the increase in Ob-Rb mRNA
expression, but decrease in protein levels, could indicate an increase in Ob-Rb receptor turn-
over or a modification in processing, producing less long-form and more of the other forms.
However, future experiments are necessary to corroborate this hypothesis. Alternatively,
although the precise dynamics of Ob-Rb regulation in these areas of the nervous system are
not completely understood, TDP-43 pathology and consequently the progression of ALS
stages may be related to disruption of leptin signaling. Of particular interest are the Akt
and STAT3 pathways downstream of the Ob-Rb receptor, as they are important targets in
the regulation of glucose and energy metabolism [50]. Indeed, we have previously reported
that TDP-43A315T mice are hypoglycemic compared to WT mice at the disease end-stage,
confirming the disturbances in the energy metabolism of the TDP-43A315T mouse model
reported previously [51]. Here, a significant decrease in serine phosphorylation of Akt was
found in the hypothalamus of TDP-43A315T mice at the end-stage, while no differences were
founded between genotypes in spinal cord tissue over the time course of the disease, which
could represent the different physiological roles that leptin exerts in these two brain areas.
In addition, while no differences in tyrosine phosphorylation of STAT3 were observed
in the hypothalamus over the time course of the disease, increased phosphorylation of
STAT3 was observed in the spinal cord of TDP-43A315T and WT mice at the end-stage of
the disease compared to the onset stage, in accordance with previous research conducted
in SOD1G93A mice [52,53].
It is conceivable that changes in leptin signaling in the spinal cord of TDP-43A315T
mice could potentially be due to a direct effect of leptin on motor neurons. Indeed, we
are currently evaluating the presence of Ob-Rb protein in TDP-43A315T mice, and our
preliminary unpublished data indicate the presence of the Ob-Rb receptor in a minority of
cells in the ventral horn of the spinal cord tissue of TDP-43A315T and WT mice that have
morphological characteristics of motor neurons. However, further studies investigating
Ob-Rb localization within the spinal cord between genotypes may be warranted.
Leptin is reported to activate POMC neurons and inhibit AgRP/NPY neurons, at
least in part through the STAT3 pathway [50]. Indeed, the regulation of glucose home-
ostasis is related to leptin signaling in the hypothalamic POMC and NPY/AgRP neurons.
Neuropeptides derived from POMC provide a strong anorexigenic effect (i.e., decreases
food intake), while NPY/AgRP neurons have a potent orexigenic effect (i.e., increase food
intake). Thus, in a situation of negative energy balance, such as the malnutrition observed
in ALS, the expression of NPY and AgRP is normally increased and POMC expression
decreased [54,55]. Consistently, our data showed an up-regulation of NPY and AgRP in
TDP-43A315T mice at disease end-stage, as previously reported by others in ALS patients
and several animal models [56,57], and an overall decrease in POMC expression. These al-
terations in metabolic neuropeptides could partly explain the hypoglycemic state observed
in TDP-43A315T mice [24]. However, collectively, these transcriptional modifications at the
end-stage of disease in TDP-43A315T mice might reflect the physiological response of the
hypothalamus to overcome adipose atrophy and loss of body weight.
One caveat of this study that should be taken into consideration is that only the
mRNA levels of hypothalamic neuropeptides and of leptin in WAT were measured, which
may or may not reflect the changes occurring in protein production. Tissue levels of a
Int. J. Mol. Sci. 2021, 22, 10305 12 of 15
secreted protein, such as, for example, leptin in adipose tissue, most likely do not reflect
modifications in its production as these proteins can be continuously secreted. The inverse
may also occur, such as in neuropeptides where an increase in cellular levels may actually
reflect reduced secretion and not increased production. Indeed, in most metabolic studies
only the mRNA levels of neuropeptides are analyzed. However, it should also be taken into
consideration that in ALS specific RNA-binding interference has been reported [58,59] that
could also alter the correlation between an mRNA and its corresponding protein levels.
5. Conclusions
In summary, our study provides the first experimental evidence suggesting that ALS
may be associated with alterations in leptin signaling pathways that might result in a leptin-
resistant state, and that this could play a critical role in the irreversible and progressive
characteristic pathological changes associated with this disease. However, the precise
pathways that could link leptin signaling to the TDP-43 proteinopathy model of ALS
remain unclear. Further mechanistic studies analyzing the consequences of leptin signaling
alterations may require the inclusion of additional defined time points, as well as larger
sample sizes. Determining the role of leptin and its mechanistic actions may provide a new
avenue for therapeutic development for this fatal condition.
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